SCN1A and Dravet syndrome: Importantly, sodium channel blockers (SCBs) are contraindicated in individuals carrying LOF variants but can be effective in those carrying GOF variants, and a specific treatment algorithm has been established for Dravet syndrome (DS), the most severe DEE linked to SCN1A mutations [2].